Erratum: Trends in breakthrough therapy designation

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Developing standards for breakthrough therapy designation in oncology.

In July 2012, Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA). The Advancing Breakthrough Therapies for Patients Act was incorporated into a Title of FDASIA to expedite clinical development of new, potential "breakthrough" drugs or treatments that show dramatic responses in early-phase studies. Using this regulatory pathway, once a promising new drug candidat...

متن کامل

Expediting drug development--the FDA's new "breakthrough therapy" designation.

The FDA's new "breakthrough therapy" designation for investigational drugs adds to the agency's portfolio of expedited programs for serious conditions. The designation requires preliminary clinical evidence demonstrating substantial improvement over existing therapies.

متن کامل

Accelerated approval and breakthrough therapy designation: oncology drug development on speed?

Recent advances in biotechnology have led to discoveries resulting in major improvements in the therapy of refractory malignancies, although most advanced cancers remain incurable. Thus, there is global consensus around the need to streamline the drug approval process for effective agents. Accelerated Approval and Breakthrough Therapy Designation hold the promise of making new treatments availa...

متن کامل

Developmental trends in targeted radionuclide therapy of neuroendocrine tumors

  Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms including carcinoids, pancreatic neuroendocrine tumors, pituitary tumors, medullary thyroid carcinoma and phaeochromocytomas. The symptoms and the outcome of NETs differ considerably between patients depending on several factors. By labelling tracers with a radioisotope, the tracer acts as a ...

متن کامل

Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union

Author details Orphan Medicines Office, European Medicines Agency, 7 Westferry Circus, Canary Wharf, London E144HB, UK. Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3, Bonn 53175, Germany. Läkemedelsverket, Dag Hammarskjölds vägen 42, Uppsala 75103, Sweden. Research Institute for Medicines (iMED.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisboa 1649-...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Nature Reviews Drug Discovery

سال: 2016

ISSN: 1474-1776,1474-1784

DOI: 10.1038/nrd.2016.43